Lung Cancer

Risk of Cancer-Specific Death May Remain Elevated for 30 Years

By

Victoria Forster, PhD

Publish Date May 17, 2022

Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.

Immunotherapy Benefits Select Patients With Late-Stage NSCLC

By

John Schieszer

Publish Date April 8, 2022

A systematic review revealed characteristics that may help clinicians predict which patients will benefit from immunotherapy.

Biosimilars as Effective as Reference Biologics for Cancer Treatment

By

Carina Storrs, PhD

Publish Date March 16, 2022

The biosimilars proved as effective as the original biologics in all cancers studied.

Combo Could Be New Standard After EGFR TKI Failure in NSCLC

Sintilimab, IBI305, and chemotherapy could be a new standard of care for patients with EGFR-mutant NSCLC that progressed on an EGFR TKI.

Lung Cancer Risk Increased for Smokers Not Offered Annual Screening

Smokers for whom annual screening with low-dose computed tomography (LDCT) is not recommended may have a high risk for lung cancer.

Myths, Ignorance Persist Around Lung Cancer: Poll

Lung cancer is the leading cause of cancer deaths in the United States, but doctors have had access to a screening tool for nearly a decade that can catch it for early treatment.

Many Elderly NSCLC Patients May Not Receive Guideline-Adherent Care

Guideline-adherent care was associated with better survival, regardless of disease stage.

Early Changes in ctDNA May Predict Treatment Outcomes in Advanced Cancer

Detection of ctDNA and early changes in ctDNA levels may predict treatment outcomes in patients with advanced solid tumors.